• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Status and Protection Against Ischemic Stroke: PheWAS, TreWAS, and More.

作者信息

Sullivan David, Bonnitcha Paul, Spinks Catherine, Keech Tony

机构信息

Central Clinical School, Sydney Medical School, University of Sydney, Camperdown, NSW, Australia (D.S., P.B., T.K.).

Department of Chemical Pathology, NSW Health Pathology (D.S., P.B., C.S.).

出版信息

Circ Genom Precis Med. 2018 Jul;11(7):e002247. doi: 10.1161/CIRCGEN.118.002247.

DOI:10.1161/CIRCGEN.118.002247
PMID:29997228
Abstract
摘要

相似文献

1
PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Status and Protection Against Ischemic Stroke: PheWAS, TreWAS, and More.前蛋白转化酶枯草溶菌素/克新9（PCSK9）状态与缺血性中风的预防：全表型组关联研究、全转录组关联研究及其他
Circ Genom Precis Med. 2018 Jul;11(7):e002247. doi: 10.1161/CIRCGEN.118.002247.
2
Genetic Regulation of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Plasma Levels: Another Piece of the Puzzle.前蛋白转化酶枯草溶菌素9型（PCSK9）血浆水平的遗传调控：谜题的又一块拼图。
Circ Genom Precis Med. 2018 May;11(5):e002165. doi: 10.1161/CIRCGEN.118.002165.
3
Unpacking and Understanding the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Apolipoprotein B Metabolism.解析并理解前蛋白转化酶枯草杆菌蛋白酶/克新蛋白酶9型抑制剂对载脂蛋白B代谢的影响
Circulation. 2017 Jan 24;135(4):363-365. doi: 10.1161/CIRCULATIONAHA.116.025897.
4
PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibition and Stroke Prevention: Another Step Forward.前蛋白转化酶枯草溶菌素9型（PCSK9）抑制与中风预防：又向前迈进了一步。
Stroke. 2020 May;51(5):1361-1362. doi: 10.1161/STROKEAHA.120.028567. Epub 2020 Apr 21.
5
Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke.前蛋白转化酶枯草杆菌蛋白酶/kexin 9型（PCSK9）在脂质代谢、动脉粥样硬化和缺血性卒中中的作用
Int J Neurosci. 2016 Aug;126(8):675-80. doi: 10.3109/00207454.2015.1057636. Epub 2015 Jul 14.
6
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor on Oxidized Lipoprotein Levels: A Case Report.前蛋白转化酶枯草溶菌素/克新9型（PCSK9）抑制剂对氧化型脂蛋白水平的影响：一例报告
J Appl Lab Med. 2020 Sep 1;5(5):1124-1126. doi: 10.1093/jalm/jfaa052.
7
Elephant in the Room: Cost of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors.
Circ Cardiovasc Qual Outcomes. 2018 Jan;11(1):e004425. doi: 10.1161/CIRCOUTCOMES.117.004425.
8
Comment on de Carvalho et al. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years. Diabetes Care 2018;41:364-367.关于德卡瓦略等人的评论。前蛋白转化酶枯草杆菌蛋白酶/克新9型（PCSK9）抑制剂与2型糖尿病发病：一项超过96000人年的系统评价和荟萃分析。《糖尿病护理》2018年；41：364 - 367。
Diabetes Care. 2018 Apr;41(4):e69. doi: 10.2337/dc17-2563.
9
Residual Risk After Treatment of Patients With Atherosclerotic Cardiovascular Disease With Proprotein Convertase Subtilisin-Kexin Type 9 Monoclonal Antibody Therapy (from the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Trial).使用前蛋白转化酶枯草溶菌素9单克隆抗体疗法治疗动脉粥样硬化性心血管疾病患者后的残余风险（来自PCSK9抑制对高风险受试者心血管结局的进一步研究试验）
Am J Cardiol. 2017 Oct 1;120(7):1220-1222. doi: 10.1016/j.amjcard.2017.06.063. Epub 2017 Jul 17.
10
Low levels of low-density lipoprotein-C associated with proprotein convertase subtilisin kexin 9 inhibition do not increase the risk of hemorrhagic transformation.与前蛋白转化酶枯草杆菌蛋白酶kexin 9抑制相关的低密度脂蛋白胆固醇水平降低不会增加出血性转化的风险。
Stroke. 2014 Oct;45(10):3086-8. doi: 10.1161/STROKEAHA.114.005958. Epub 2014 Aug 14.